Related Experiment Videos
Biologic therapies for inflammatory eye disease.
Lyndell Lim1, Eric B Suhler, Justine R Smith
1Casey Eye Institute, Oregon Health and Science University, 3375 SSW Terwilliger Boulevard, Portland, Oregon 97239, USA.
Clinical & Experimental Ophthalmology
|June 13, 2006
Summary
Biologic therapies offer new hope for difficult-to-treat inflammatory eye conditions like uveitis. While effective, these advanced treatments come with significant costs and potential serious side effects.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Biologic therapies represent a significant advancement in treating inflammatory eye diseases.
- Traditional treatments are often insufficient for severe or recalcitrant cases.
Purpose of the Study:
- To review the current use of biologic agents for inflammatory eye conditions.
- To summarize published data on biologics for uveitis, scleritis, and orbital inflammation.
Main Methods:
- Literature review of published studies on biologic therapies.
- Inclusion of agents like TNF blockers, daclizumab, rituximab, interferons, and IVIg.
Main Results:
- Biologics show promise in treating resistant ocular inflammation, with reports of dramatic recoveries.
- Tumor necrosis factor blockers, daclizumab, and rituximab are key agents discussed.
Conclusions:
- Biologic therapies offer novel treatment options for refractory inflammatory eye diseases.
- The high cost and potential for serious complications necessitate careful patient selection and monitoring.